Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q3 FY23 results · Oct–Dec 2022
Suven Life Sciences reported revenue from operations of ₹3.00 crore (down 32.3% from Q3 FY22) and net loss of ₹51.12 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.00 | 4.43 | −32.3% | 4.39 | −31.6% |
| Other income | 2.20 | 0.14 | 16x | 0.21 | +969.8% |
| Total income | 5.21 | 4.57 | +13.9% | 4.59 | +13.4% |
| Profit before tax | (51.12) | (33.69) | Loss widened | (23.18) | Loss widened |
| Net profit for the period | (51.12) | (33.69) | Loss widened | (23.18) | Loss widened |
| EPS, basic (₹) | (2.90) | (2.65) | not comparable | (1.59) | not comparable |
| Net margin (%) | -1702.5 | -760.0 | -528.5 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.00 | 4.43 | −32.3% | 4.39 | −31.6% |
| Other income | 2.20 | 0.14 | 16x | 0.21 | +969.8% |
| Total income | 5.21 | 4.57 | +13.9% | 4.59 | +13.4% |
| Profit before tax | (6.63) | (8.22) | Loss narrowed | (8.93) | Loss narrowed |
| Net profit for the period | (6.63) | (8.22) | Loss narrowed | (8.93) | Loss narrowed |
| EPS, basic (₹) | (0.35) | (0.65) | not comparable | 0.61 | not comparable |
| Net margin (%) | -220.9 | -185.4 | -203.6 |
Consolidated
- Filed with BSE
- 07 Feb 2023, 14:56 IST
- Board meeting
- 02 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2023, 14:56 IST
- Board meeting
- 02 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE